Published date: Feb 11 2020

Journal Title: KnE Life Sciences

Issue title: The 2019 International Conference on Biotechnology and Life Sciences (IC-BIOLIS)

Pages:

DOI: 10.18502/kls.v5i2.6448

Conny Riana Tjampakasariconnyrianat@yahoo.comDepartment of Microbiology, Faculty of Medicine, University of Indonesia

Andi YasmonDepartment of Microbiology, Faculty of Medicine, University of Indonesia

Agus SjahrurachmanDepartment of Microbiology, Faculty of Medicine, University of Indonesia

Samsuridjal DjauziDepartment of Allergy Immunology, RSCM, Faculty of Medicine, University of Indonesia

Pneumocystis jirovecii is known to cause opportunistic infections in the lower respiratory tract in individuals with low immune systems, especially patient with HIV infection. The prevalence of P. jirovecii pneumonia (PjP) in various countries show varying numbers. In Indonesia, HIV cases continue to rise. However, the data in Indonesia concerning the case of PjP is very limited. Until now the prevalence of PjP in Indonesia is only based on clinical symptoms of the patient. Currently, diagnosis of PjP relies on microscopic examination. The disadvantage of this examination is not easy to do and has a high negative predictive value. Thus, this study was conducted to develop a molecular test to diagnose PjP infection in HIV-AIDS suspected pneumonia. Molecular diagnostic test aimed for Major Surface Glycoprotein (MSG) gene of P. jirovecii detection was done through real-time PCR against 100 sputum samples. Demographic data show that the prevalence of PjP infection in HIV-AIDS suspected pneumonia patients in Jakarta is 20.0%, male 75% within 31-40 y.o (35%), dominant (80%) from patients with CD⁴⁺ T-lymphocytes of 200-349 cells/µL. Molecular real-time PCR methods were shown to give five times sensitivity higher than Giemsa stain.

Keywords: P. jirovecii, HIV, real-time PCR

[1] James RS, Charles BB, Robert FM, and Ann EW. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerg Infect Dis. 2002;8(9):891-6


[2] Nimri LF, Moura, Moura INS, Huang L, Rio CD, Duchin JS, Dotson EM and Beard CB. Genetic Diversity of Pneumocystis carinii f. sp. hominis based on variations in nucleotide sequences of internal transcribed spacers of rRNA Genes. J Clin Microbiol. 2002;40(4):1146-51


[3] Kwon Chung KJ and Bennet JE. Medical mycology. Philadelphia: Lea & Febriger; 1992.p.369-76


[4] Miller RF, Huang L and Walzer PD. Pneumocystis Pneumonia associated with human immunodeficiency virus. Clin Chest Med. 2013;34: 356-61


[5] Morris A, Wei K, Afshar K and Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008; 197:10-7


[6] Morris A and Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. J ASM Org Am Soc Microbiol. 2012;25(2): 297-317


[7] Khalife S, Aliouat EM, Aliouat CM, Gantois N, Devos P, Mallat H, Del-Cas E, Dobbousi F, Hamze M and Realle E. First data on Pneumocystis jirovecii colonization in patients with respiratory diseases in north Lebanon. N Microb N Infect. July 2015;6:11-4


[8] Han K, Mra R, Saw H and Naing W. Pneumocustis carinii infection among Human Immunodeficiency Virus infected Myanmar pasient. Parasitology Research Division, Departmen of Medical Research Myanmar. South Asian J Trop Med Publ Health. 2011;48:103-5


[9] Pohan HT. Oppurtunistic infection of HIV-infected/AIDS patients in Indonesia: problems and challenge. Acta Med Indon. 2006;38:169-73


[10] Rozaliyani A. Karakteristik klinis, radiologis dan laboratoris pneumonia Pneumocystis pada pasien AIDS dengan gejala pneumonia di beberapa rumah sakit di Jakarta. Jakarta: Medical Research Unit FKUI; 2009.h. 22-51


[11] Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, Roberts JM, Hightower AW, Bens MS, Freeman AR, Lee S, Stringer JR, Duchin JS, del Rio C, Rimland D, Baughman RP, Levy DA, Dietz VJ, Simon P and Navin TR. Genetic variation in Pneumocystis carinii isolates from different geographicregions: amplications for transmission. Emerg Infect Dis. 2000;6:65–272


[12] Heelan JS and Ingensol FW. Essentials of human parasitology. United States: Delmar; 2002.p.130-1


[13] Murray PR, Rosenthal KS, Kobayashi GS, Knapp JS and Rice RJ. Manual of clinical microbiology, 6th ed. Washington: DC. ASM Press; 1995. p.432-36


[14] Knap and Pfaller MA. Medical microbiology, 4th Ed. USA: Mosby, Missoury; 2002.p.162-66


[15] Robert V, Theodore J. Kottom, Joseph E. Standing and Andrew H. “Limper” vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Resp Cell Mol Biol. 2001;25(2):203-211



[16] Krajicek BJ, Limper AH and Thomas CF Jr. Advances and the biology, pathogenesis and identification of Pneumocystis pneumonia. Curr Opin Pulm Med. 2008; 14:228


[17] Tsolaki AG and Miller RF. Genetic diversity at the internal transcribed spacers regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J Infect Dis. 1996: 324-31


[18] Esteves F, Gaspar J, Marques T, Leite R, Antunes F, Mansinho K and Matos O. Identification of relevant single-nucleotide polymorphisms in Pneumocystis jiroveci: relationship with clinical data. Clin Microbiol Infect. 2010;16: 878-84.


[19] Meneau I, Sanglard D, Bille J and Hauser MP. Pneumocystis jirovecii dihydropteroate synthase polymorphisms confer resistance to sulfadoxine and sulfanilamide in Saccharomyces cerevisiae.Antimicrob Agents Chemo. 2004;7: 2610-6


[20] Valerio A, Tronconi E, Mazza F, Fantoni G and Atzori C. Genotyping of Pneumocystis jirovecii pneumonia in Italian AIDS patients: Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr. 2007;45(5): 521-8


[21] Jarboui MA, Mseddi F, Sellami A, Makni F and Ayadi A. Genetic diversity of Pneumocystis jirovecii strains based on sequence variation of different DNA region. Med Mycol. 2013;51: 561–7


[22] Brown HW and Neva FA. Basic clinical parasitology. United States of America: Appleton Century Crofts;1983.p.76-7


[23] Marijke JV, Vera EJK, Catherin AB, Walther NKA van Mook and Catharina FML. Molecular epidemiology of Pneumocystis jirovecii in human immunodeficiency virus-positive and -negative immunocompromised patients in The Netherlands. J Med Microbiol. 2014;63:1294–1302. DOI 10.1099/jmm.0.076257-0


[24] Dimonte S, Berrilli F, D’Orazi C, D’Alfonso R, Placco F, Bordi E, Perno CF and Di Cave. Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy. Inf Gen Evol. 2013;14:68–72


[25] Kementrian Kesehatan RI. Data HIV AIDS di Indonesia. 2015.


[26] Kementerian Kesehatan Republik Indonesia Direktorat Jendral Penyehatan Lingkungan dan Pengendalian Penyakit. Laporan perkembangan HIV-AIDS triwulan 4 tahun 2013.


[27] Pneumonia Komuniti. Pedoman diagnosis dan penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia. 2003


[28] Yunihastuti E, Djauzi S dan Zubairi D. Infeksi oportunistik pada AIDS. Jakarta: Balai penerbit FKUI;2005,h.1-78.


[29] Agustina DR, Efiyanti C, Yunihastuti E, Ujainah A, Rozaliyani A. Diagnosis dan tata taksana Pneumocystis carinii Pneumonia (PCP)/Pneumocystis jirovecii Pneumonia pada pasien HIV: Sebuah Laporan Kasus. Jurnal Penyakit Dalam Indon. 2017; 4(4):209-13.


[30] Charles FT, Andrew HL. 2008. Pneumocystis Pneumonia. The New Eng J Med. 2008;350: 2487-98.


[31] World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunoligical classification of HIV-related disease in adults and children. WHO press; 2006.p.1-38.


[32] Robert GF, Belaz S, Revest M Tattevin P, Jouneau S and Decaux O. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study.J Clin Microbiol. 2014;52(9): 3370


[33] Rodriguez YDA, Wissmann G, Muller AL, Pederiva MA, Brum MC, and Brackmann RL. Pneumocystis jirovecii pneumonia in developing countries. J Par.2011;18(3): 219-228


[34] Meja R, Laetittia V, Patrick T, Aimable N, Rene PG and Philippe MH. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerg Infect Dis.2013;19:21-8


[35] Tia T, Putapotntip C, Kosuwin, R, Kongpolprom, N, Kawkitinarong, K and Jongwitiwes S. A Highly sensitivity novel PCR assay for detection of Pnemocystis jirovecii DNA in bronchoalveolar lavage specimens from immunocompromised patients. Original Articles. Mycology. Clin Microbiol Infect. 2011:589-603


[36] Pierre F, Bahrie B, Fabrice D, Helene R, Ce´line C, Jamal H, Frederic L and Roger TMS. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jirovecii pneumonia from bronchoalveolar lavage specimens. J Med Microbiol. 2004; 53: 603–7


[37] Florence RG, Sorya B, Matthieu R, Pierre T, Stéphane J, Olivier DSC, Yves LT and Jean-Pierre G. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study. J Clin Microbiol. 2014;52(9): 3370-6


[38] Gupta R, Mirdha BR, Guleria R, Mohan A, Kabra SK, Kumar L, Agarwal SK and Luthra K. Use of different primer sequence smplification by polymerase chain reaction for identification of Pneumocystis jirovecii in clinical samples. Ind J Chest Dis All Sci. 2008;50: 321-7


[39] Muhlethaler K, Bogil SK, Wasmer S, Von Garnier C, Dumont P, Rauch A, Muhlemann K and Garzoni C. Quantitative PCR to diagnose pneumocystis pneumonia in immunocompromised non HIV patients. Europ Resp J. 2002; 29(4): 971-8


[40] Francoise B, Odile C, Francoise F, Catherine C, Jean Mar C and Stepahnie B. Clinical significance of quantifing Pneumocystis jirovecii DNA by using real time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol. 2012;509(2): 227-31


[41] Singh S, Mirdha BR, Singh P, Guilera R, Mohan JA, Agarwal SK, Kabra SK and Pandey RM. Quantitative real time PCR assay for differentiation between pneumocystis pneumonia and pneumocystis colonization. Intern J Med Clin Res. 2014;5(1):285-94